CN1305892C - 已知的噻吩甲酸十二氢环戊二烯并(a)菲基酯的多晶型 - Google Patents

已知的噻吩甲酸十二氢环戊二烯并(a)菲基酯的多晶型 Download PDF

Info

Publication number
CN1305892C
CN1305892C CNB038180596A CN03818059A CN1305892C CN 1305892 C CN1305892 C CN 1305892C CN B038180596 A CNB038180596 A CN B038180596A CN 03818059 A CN03818059 A CN 03818059A CN 1305892 C CN1305892 C CN 1305892C
Authority
CN
China
Prior art keywords
formula
compound
inflammatory
treatment
crystalline form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB038180596A
Other languages
English (en)
Chinese (zh)
Other versions
CN1671731A (zh
Inventor
G·约尔丁
M·马兹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN1671731A publication Critical patent/CN1671731A/zh
Application granted granted Critical
Publication of CN1305892C publication Critical patent/CN1305892C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J33/00—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J33/00—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J33/002—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CNB038180596A 2002-07-29 2003-07-28 已知的噻吩甲酸十二氢环戊二烯并(a)菲基酯的多晶型 Expired - Fee Related CN1305892C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0217504.0 2002-07-29
GBGB0217504.0A GB0217504D0 (en) 2002-07-29 2002-07-29 Organic compounds

Publications (2)

Publication Number Publication Date
CN1671731A CN1671731A (zh) 2005-09-21
CN1305892C true CN1305892C (zh) 2007-03-21

Family

ID=9941275

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB038180596A Expired - Fee Related CN1305892C (zh) 2002-07-29 2003-07-28 已知的噻吩甲酸十二氢环戊二烯并(a)菲基酯的多晶型

Country Status (30)

Country Link
US (1) US7683048B2 (enExample)
EP (2) EP1554303B1 (enExample)
JP (1) JP2006501207A (enExample)
KR (1) KR100688371B1 (enExample)
CN (1) CN1305892C (enExample)
AR (1) AR040692A1 (enExample)
AT (1) ATE349459T1 (enExample)
AU (1) AU2003251651B2 (enExample)
BR (1) BR0313044A (enExample)
CA (1) CA2493330C (enExample)
CY (1) CY1106406T1 (enExample)
DE (1) DE60310747T2 (enExample)
DK (1) DK1554303T3 (enExample)
EC (1) ECSP055579A (enExample)
ES (1) ES2279970T3 (enExample)
GB (1) GB0217504D0 (enExample)
HK (1) HK1080484B (enExample)
IL (2) IL166287A0 (enExample)
MX (1) MXPA05001173A (enExample)
MY (1) MY136407A (enExample)
NO (1) NO20050806L (enExample)
NZ (2) NZ537868A (enExample)
PE (1) PE20040722A1 (enExample)
PL (1) PL209409B1 (enExample)
PT (1) PT1554303E (enExample)
RU (2) RU2348646C1 (enExample)
SI (1) SI1554303T1 (enExample)
TW (1) TWI309164B (enExample)
WO (1) WO2004013156A1 (enExample)
ZA (1) ZA200500370B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0019172D0 (en) 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
AU7576001A (en) 2000-08-05 2002-02-18 Glaxo Group Ltd 6.alpha., 9.alpha.-difluoro-17.alpha.-`(2-furanylcarboxyl) oxy]-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4,-diene-17-carbothioic acid s-fluoromethyl ester as an anti-inflammatory agent
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
US6777399B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
WO2002088167A1 (en) 2001-04-30 2002-11-07 Glaxo Group Limited Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
GB0523654D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523656D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0603783D0 (en) * 2006-02-24 2006-04-05 Novartis Ag Organic compounds
CN103622962A (zh) * 2008-03-14 2014-03-12 大塚制药株式会社 制剂组合物在制备治疗以mmp-2及/或mmp-9为起因的纤维症的药物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08291073A (ja) * 1995-04-22 1996-11-05 Kissei Pharmaceut Co Ltd 医薬品組成物及びその製造方法
WO2002000679A2 (en) * 2000-06-28 2002-01-03 Novartis Ag 9.alpha.-chloro-6.alpha.-fluoro-17.alpha.-hydroxy-16-methyl-17-beta-methoxycarbonyl-androst-1,4-dienes esterified in position 17.alpha. by a cyclic acyl group

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU550939A1 (ru) * 1975-05-19 1994-07-15 Институт химии древесины АН ЛатвССР 1,2,3,4,4а,4в,5,6,10,10а -декагидро -6- хлорацетоксиметил -1,4а-диметил -7- (1-метилэтил) -1- фенантренкарбоновая кислота или ее соли

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08291073A (ja) * 1995-04-22 1996-11-05 Kissei Pharmaceut Co Ltd 医薬品組成物及びその製造方法
WO2002000679A2 (en) * 2000-06-28 2002-01-03 Novartis Ag 9.alpha.-chloro-6.alpha.-fluoro-17.alpha.-hydroxy-16-methyl-17-beta-methoxycarbonyl-androst-1,4-dienes esterified in position 17.alpha. by a cyclic acyl group

Also Published As

Publication number Publication date
TWI309164B (en) 2009-05-01
CN1671731A (zh) 2005-09-21
HK1080484A1 (en) 2006-04-28
EP1554303B1 (en) 2006-12-27
PL209409B1 (pl) 2011-08-31
RU2330043C2 (ru) 2008-07-27
NZ537868A (en) 2006-11-30
PE20040722A1 (es) 2004-11-29
US7683048B2 (en) 2010-03-23
PT1554303E (pt) 2007-03-30
MXPA05001173A (es) 2005-05-16
IL184848A0 (en) 2007-12-03
JP2006501207A (ja) 2006-01-12
ES2279970T3 (es) 2007-09-01
GB0217504D0 (en) 2002-09-04
DK1554303T3 (da) 2007-04-30
ZA200500370B (en) 2006-07-26
NO20050806L (no) 2005-02-15
CA2493330A1 (en) 2004-02-12
DE60310747D1 (en) 2007-02-08
CY1106406T1 (el) 2011-10-12
CA2493330C (en) 2011-08-23
AR040692A1 (es) 2005-04-13
NZ549713A (en) 2008-04-30
EP1554303A1 (en) 2005-07-20
IL166287A0 (en) 2006-01-15
HK1080484B (en) 2007-08-03
DE60310747T2 (de) 2007-10-11
ECSP055579A (es) 2005-04-18
KR100688371B1 (ko) 2007-03-02
BR0313044A (pt) 2005-06-14
WO2004013156A1 (en) 2004-02-12
MY136407A (en) 2008-09-30
EP1676854A1 (en) 2006-07-05
AU2003251651B2 (en) 2007-07-12
AU2003251651A1 (en) 2004-02-23
TW200401633A (en) 2004-02-01
RU2007143025A (ru) 2009-01-20
RU2005105688A (ru) 2005-10-10
US20060166954A1 (en) 2006-07-27
PL373140A1 (en) 2005-08-22
ATE349459T1 (de) 2007-01-15
KR20050033632A (ko) 2005-04-12
SI1554303T1 (sl) 2007-06-30
RU2348646C1 (ru) 2009-03-10

Similar Documents

Publication Publication Date Title
EP1341542B1 (en) Indanylderivatives for treating airway diseases
EP3603634A1 (en) Pharmaceutical composition containing glycopyrrolate and a beta2 adrenoceptor agonist
CN1305892C (zh) 已知的噻吩甲酸十二氢环戊二烯并(a)菲基酯的多晶型
US20080279948A1 (en) Treatment of Asthma and Copd Using Triple-Combination Therapy
CN101511794A (zh) 作为β-肾上腺素受体激动剂的茚满-2-基氨基-羟基乙基-喹啉酮马来酸盐衍生物的多晶形式
MX2009002300A (es) Polimorfo de bromuro de (r)-3-(2-hidroxi-2,2-difenil-acetoxi)-1-(i soxazol-3-il-carbamoil-metil)-1-azonia-biciclo-[2.2.2]-octano.
HK1095333A (en) Polymorphs of a known thiophenecarboxylic acid dodecahydrocyclopenta[a]phenanthrenyl ester
AU2007202962A1 (en) Polymorphis of a known thiophenecarboxylic acid dodecahydrocyclopenta (A) phenanthrenyl ester
HK1059564B (en) Indanylderivatives for treating airway diseases
HK1108364A (en) Organic compounds

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: NOVARTIS CO., LTD.

Free format text: FORMER NAME: NOVARTIS AG

CP01 Change in the name or title of a patent holder

Address after: Basel

Patentee after: Novartis Ag

Address before: Basel

Patentee before: Novartis AG

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20070321

Termination date: 20140728

EXPY Termination of patent right or utility model